NCT05168618View on ClinicalTrials.gov

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

January 31, 2027

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
BIOLOGICAL

Atezolizumab

Given IV

DRUG

Cabozantinib S-malate

Given PO

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Utah

OTHER